NCT06448585CompletedPhase 4
Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy.
Effectiveness of a Dietary Supplement Based on a Synergistic Combination of Beta-Glucans and Saccharomyces Cerevisiae Yeast Enriched With Zinc and Selenium in Allergic Patients Undergoing Subcutaneous Immunotherapy Study.
Source: ClinicalTrials.gov · Last updated 29 Aug 2025
Brief summary (registry, in English)
The present study will attempt to determine if the dietary supplement, based on a synergistic combination of β-glucans and Saccharomyces cerevisiae yeast enriched with Zinc and Selenium, can improve the immune response in allergic patients diagnosed with rhinitis or rhinoconjunctivitis, with or without controlled asthma, who are undergoing subcutaneous polymerized 100 immunotherapy with a rapid initiation protocol. It will also attempt to determine if the dietary supplement in combination with DAO enzyme could improve the immunological response to immunotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 4 Jun 2024
- Start date
- 29 May 2024
- Primary completion date
- 29 May 2024
- Lead sponsor
- Gala Servicios Clinicos S.L.
- Diseases
- Asthma
- NCT number
- NCT06448585
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 60
- From 29 May 2024 to the primary completion date, 29 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of intolerance or hypersensitivity to selenium or zinc, or to any of the components of the dietary supplement individually.
- Personal history of liver or kidney disease.
- Any condition that, in the opinion of the investigators, renders the subject unable to participate in the study.
Age
- Outside the age range specified for the study.
Other
- Refusal to sign the informed consent.
- Participation in a clinical trial within the past two months, or currently participating in another study.
- Excessive alcohol consumption (\> 20 grams/day) or use of substance abuse.
Who the study is looking for
- Age between 18 and 65 years.
- Both sexes.
- Patients diagnosed with allergic rhinitis or allergic rhinoconjunctivitis, with or without allergic asthma due to sensitization to aeroallergens, undergoing treatment with subcutaneous polymerized 100 immunotherapy, initiating treatment with rapid dosing.
- Normoglycemia (fasting glucose ≤ 100 mg/dL).
- BMI between 18.5-29.9 kg/m².
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| GALA Laboratories Coordinator of this site? Confirm its status | Don Benito | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.